Ipswich Investment Management Co. Inc. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 37.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,155 shares of the biopharmaceutical company’s stock after selling 3,096 shares during the period. Ipswich Investment Management Co. Inc.’s holdings in Gilead Sciences were worth $397,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Baldwin Brothers Inc. MA grew its holdings in shares of Gilead Sciences by 63.3% during the 1st quarter. Baldwin Brothers Inc. MA now owns 351 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 136 shares during the last quarter. Engrave Wealth Partners LLC purchased a new stake in Gilead Sciences during the 4th quarter valued at about $29,000. Bainco International Investors purchased a new stake in shares of Gilead Sciences during the first quarter valued at approximately $29,000. EPG Wealth Management LLC raised its holdings in Gilead Sciences by 186.7% during the 1st quarter. EPG Wealth Management LLC now owns 410 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 267 shares during the last quarter. Finally, Archer Investment Corp bought a new position in shares of Gilead Sciences during the fourth quarter valued at about $33,000. Hedge funds and other institutional investors own 80.15% of the company’s stock.

A number of equities analysts recently commented on GILD shares. Cantor Fitzgerald upped their target price on Gilead Sciences from $78.00 to $86.00 and gave the company an “overweight” rating in a report on Tuesday, April 7th. Mizuho reiterated a “buy” rating and set a $81.00 target price on shares of Gilead Sciences in a report on Wednesday, May 13th. ValuEngine lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Friday, May 1st. Cfra increased their price objective on Gilead Sciences from $71.00 to $74.00 and gave the stock a “sell” rating in a report on Wednesday, April 29th. Finally, DZ Bank reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Monday, June 15th. Five investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $79.65.

In other Gilead Sciences news, Director John Francis Cogan sold 2,413 shares of the firm’s stock in a transaction on Monday, April 13th. The stock was sold at an average price of $75.90, for a total value of $183,146.70. Following the completion of the sale, the director now directly owns 57,273 shares of the company’s stock, valued at approximately $4,347,020.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Brett A. Pletcher sold 13,210 shares of the business’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total transaction of $1,046,628.30. Following the transaction, the executive vice president now directly owns 27,204 shares in the company, valued at approximately $2,155,372.92. The disclosure for this sale can be found here. Over the last three months, insiders sold 35,318 shares of company stock valued at $2,816,854. 0.13% of the stock is owned by corporate insiders.

GILD stock opened at $74.71 on Friday. The company has a quick ratio of 2.92, a current ratio of 3.04 and a debt-to-equity ratio of 1.00. Gilead Sciences, Inc. has a 52 week low of $60.89 and a 52 week high of $85.97. The firm has a 50 day moving average of $75.37 and a 200 day moving average of $72.48. The stock has a market capitalization of $93.71 billion, a PE ratio of 19.21, a price-to-earnings-growth ratio of 3.29 and a beta of 0.70.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.57 by $0.11. Gilead Sciences had a net margin of 21.84% and a return on equity of 35.44%. The company had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.44 billion. During the same quarter last year, the business earned $1.67 earnings per share. The firm’s revenue was up 5.1% on a year-over-year basis. On average, equities research analysts expect that Gilead Sciences, Inc. will post 6.64 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Friday, June 12th were paid a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a dividend yield of 3.64%. The ex-dividend date was Thursday, June 11th. Gilead Sciences’s dividend payout ratio is presently 44.30%.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: Price-Sales Ratio

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.